Coherus Biosciences (8C5) Stock Statistics & Valuation Metrics

Coherus Biosciences has a market cap or net worth of CHF182.59M. The enterprise value is CHF165.61.

Coherus Biosciences has 154,500,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Coherus Biosciences’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -151.77%.

The current PE Ratio of Coherus Biosciences is ―. Coherus Biosciences’s PEG ratio is 0.00144.

In the last 12 months, Coherus Biosciences had revenue of 42.17M and earned -170.29M in profits. Earnings per share was -1.45.

In the last 12 months, operating cash flow was -243.92M and capital expenditures 0.00, giving a free cash flow of -243.92M billion.

Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Coherus Biosciences upcoming earnings date is Nov 9, 2026, After Close (Confirmed).

Coherus Biosciences as a current ratio of 1.46, with Debt / Equity ratio of 61.98%

In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.

Coherus Biosciences EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -0.88.

Coherus Biosciences has CHF105.31M in cash and marketable securities with CHF37.71M in debt, giving a net cash position of CHF67.60M billion.

Gross margin is 63.55%, with operating margin of -425.72%, and net profit margin of -403.80%.

The average price target for Coherus Biosciences is CHF6.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy